Illumina announces expansion of TruSight Oncology portfolio [Yahoo! Finance]
Illumina, Inc. (ILMN)
Last illumina, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
illumina.com/company/investor-information.html
Company Research
Source: Yahoo! Finance
Customer-led research and presentations at the conference will deliver the latest evidence and education in tumor profiling SAN DIEGO Nov. 19, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will release TruSight ™ Oncology 500 v2 (TSO 500 v2), a new version of its flagship cancer research assay to enable comprehensive genomic profiling (CGP). The assay is currently under development, with global release planned for mid-2025. Detailed plans for the product will be shared November 21 in a spotlight presentation at the annual meeting of the Association of Molecular Pathology (AMP) in Vancouver, British Columbia TSO 500 v2 assesses hundreds of genes across all variant classes, and immuno-oncology biomarkers, in a single assay from one sample, to facilitate therapy selection research. Key features of TSO 500 v2 include: Faster turnaround time and reduced hands-on time Sensitive variant c
Show less
Read more
Impact Snapshot
Event Time:
ILMN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ILMN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ILMN alerts
High impacting Illumina, Inc. news events
Weekly update
A roundup of the hottest topics
ILMN
News
- Preimplantation Genetic Testing Market Set to Reach $1.2 Billion by 2031, Driven by Advances in Genetic Screening and Growing IVF Demand: Market Research Intellect [Yahoo! Finance]Yahoo! Finance
- Illumina announces expansion of TruSight Oncology portfolioPR Newswire
- INITIATE Ventures Closes $45 Million to Fund and Co-create Companies at the Intersection of Healthcare, Life Sciences, and TechPR Web
- Illumina, Inc. (NASDAQ: ILMN) had its price target raised by analysts at Stephens from $170.00 to $184.00. They now have an "overweight" rating on the stock.MarketBeat
- Illumina, Inc. (NASDAQ: ILMN) had its "equal weight" rating re-affirmed by analysts at Morgan Stanley. They now have a $156.00 price target on the stock.MarketBeat
ILMN
Earnings
- 11/4/24 - Beat
ILMN
Sec Filings
- 11/12/24 - Form SC
- 11/7/24 - Form 4
- 11/7/24 - Form 4
- ILMN's page on the SEC website